lifestyle.smarttalksuccess.com

Author: ELI LILLY AND COMPANY

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

January 30, 2026
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

January 21, 2026
Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

January 20, 2026
Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

January 14, 2026
Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

January 13, 2026
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

January 7, 2026
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

December 30, 2025
Lilly to participate in J.P. Morgan Healthcare Conference

December 17, 2025
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama

December 10, 2025
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

December 9, 2025